Trial Tuesday: China's ASCO Moment

A crowd the size of a sold-out Foo Fighters stadium show, some 40,000-plus physicians, researchers, industry executives and patients, will gather in Chicago at the end of this week for the world's biggest cancer conference. The data, as always, will be the headline act. This year, for the first time, the plenary slot belongs to China.

Akeso and Summit Therapeutics will take that stage with overall survival data from HARMONi-6. If you have been watching how fast the Chinese pipeline has been moving, you already know what a plenary slot implies.

If you have not, this edition is your catch-up.

Akeso and Summit Therapeutics will present overall survival data from HARMONi-6 at the ASCO plenary on June 1, pitting their dual PD-1xVEGF inhibitor ivonescimab against BeiGene's tislelizumab in frontline NSCLC. The trial cleared its progression-free survival bar last year. A plenary slot does not go to a miss.

THE CHATTER: The analyst concern circulating before the readout is specific: even a clean OS result with an HR around 0.75 in HARMONi-6 may not move the needle on Summit's ability to replicate in global trials. The China-only design is a feature for regulatory purposes and a liability for investor confidence. The question on the floor at ASCO will not be "did it work?" It will be "does it work here?"

WHY YOU SHOULD CARE: If your pipeline touches NSCLC, PD-1, or VEGF combinations, the plenary data changes your comp set regardless of what happens in global trials. More immediately: the BD implications around ivonescimab's platform depend heavily on whether Summit can close the bridging argument. If they cannot, the asset's ex-China value stays contested. That is a negotiating window for anyone looking at licensing or co-development in markets where HARMONi-3 data will matter.

LOOK OUT FOR: HARMONi-3 global data is the next real test. No readout date has been confirmed, but Summit has indicated Phase III enrollment is complete. Watch for a data disclosure timeline at the investor event running alongside ASCO this week.

Revolution Medicines will present full Phase III data from RASolute 302 at ASCO this week. Daraxonrasib delivered median overall survival of 13.2 months versus 6.7 months on chemotherapy in previously treated metastatic PDAC. The hazard ratio was 0.40.

WHAT HAPPENED: Revolution toplined the endpoint hit earlier this year. The detailed data coming at ASCO will give the field its first proper look at the subgroup cuts, durability, and safety profile. Daraxonrasib is an oral RAS(ON) multi-selective inhibitor, targeting the full activated RAS pool rather than a single mutation. That mechanism matters because only around 1-2% of PDAC patients carry KRAS G12C, the mutation that first-generation KRAS inhibitors were built for. Revolution is building for the broader population, and the OS number suggests it has something to build on.

WHY YOU SHOULD CARE: An HR of 0.40 in second-line PDAC is the kind of number that rewrites competitive dynamics fast. If the ASCO presentation holds up at the subgroup level, daraxonrasib becomes the asset everyone in oncology BD is calling their KRAS team about before the session ends. Revolution also has zoldonrasib, a G12D-selective inhibitor, in Phase III for the same indication. Two Phase III programs in PDAC at the same company is unusual. What it means for combination strategy, label breadth, and partnership conversations is not yet settled.

LOOK OUT FOR: The subgroup data at ASCO. If the OS benefit is consistent across KRAS mutation status rather than driven by a specific variant, the addressable population expands and the regulatory conversation changes. FDA has granted daraxonrasib Fast Track and Breakthrough Therapy designations. An NDA filing timeline should follow the ASCO presentation.

Eli Lilly's Phase III TRIUMPH-1 data showed retatrutide, its GIP/GLP-1/glucagon triple agonist, produced weight loss exceeding 30% in more than 45% of patients on the highest dose over 80 weeks. Bariatric surgery typically delivers 25-30% at one to two years.

WHAT HAPPENED: All three doses hit primary and key secondary endpoints. The 12mg dose posted 21% placebo-adjusted weight loss at 80 weeks, compared with Zepbound's 18% in its pivotal trial. The tolerability profile matters here: analysts flagged that retatrutide will likely be positioned toward patients at the higher end of the BMI range, not as a broad replacement for tirzepatide. Lilly's own commercial logic confirms it. Evaluate projects retatrutide at $5.8bn by 2032. Zepbound is projected at $27.9bn peak in 2030. Lilly has built a portfolio with a deliberate hierarchy. Retatrutide sits at the top of it by efficacy. Zepbound does the volume.

THE CHATTER: The data point nobody is quite saying out loud: real-world data presented at ASCO this week suggests GLP-1 drugs may reduce metastatic progression in obesity-related cancers, including lung, breast, colorectal, and liver. ASCO's chief medical officer called for a prospective randomized trial to separate the drug effect from the health engagement effect of GLP-1 users. That trial will be run eventually. When it is, the label implications for tirzepatide and retatrutide are not small.

WHY YOU SHOULD CARE: Retatrutide's TRIUMPH-1 data tightens the competitive math for anyone in the obesity space or adjacent to it. The surgery-level weight loss framing gives Lilly a new narrative above the current GLP-1 ceiling. If you are working on a combination program, a device play, or a platform that depends on GLP-1 co-administration, the tolerability question at the high-BMI end is now the variable that shapes your patient population assumptions.

LOOK OUT FOR: The TRIUMPH-1 full dataset, including cardiovascular outcomes, will determine whether retatrutide can claim a broader label than Zepbound or whether it stays a high-potency tier product. The GLP-1/cancer randomized trial, when it is eventually designed, will also create a new endpoint conversation for ongoing obesity programs. That is a two-to-three year story, but the data being discussed at ASCO this week is where it starts.

Forty thousand people will spend this week in Chicago. The data will tell us who was right.

See you tomorrow.